reports
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
Cancellation of remaining publicly held registered shares of Vifor Pha...
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share"). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court. Vifor further announced today that SIX Exchange Regulation AG h...
Ferinject® approved in Chinafor the treatment of iron deficiency in ad...
ST. GALLEN, Switzerland & BEIJING--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide. “We...
Approval of extension of exemptions from SIX disclosure and publicity ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor Pharma AG's ad hoc announcement of August 2, 2022). The relevant parts of the decision of SER of October 19, 2022, are as follows: "I. Die Vifor Pharma AG (Emittent) wird im Hinblick auf die geplante Dekotierung bis und m...
Approval of delisting of Vifor Pharma AG's registered shares
ST. GALLEN, SWITZERLAND--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's registered shares. On August 18, Vifor applied to SIX Exchange Regulation AG (SER) for the delisting of the totality of its registered shares. With its decision of October 11, 2022, SER approved the delisting of all registered shares of Vifor with a par value of CHF 0.01 each. SER will determine the last trading day and the delisting date in consultation with Vi...
Swissmedic accorde à Tavneos® l’autorisation de mise sur le marché pou...
SAINT- GALL, Suisse--(BUSINESS WIRE)-- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) a annoncé aujourd’hui que l’Institut suisse des produits thérapeutiques Swissmedic a autorisé la mise sur le marché de Tavneos® comme traitement d’appoint d’un régime immunosuppresseur standard à base de rituximab ou cyclophosphamide avec glucocorticoïdes, est indiqué dans le traitement des patients adultes atteints de vascularite active, sévère granulomatose avec polyangéite (GPA) et polyangéite microscopique (PAM), les deux principales formes de vascularite associée aux ANCA. Tavneos® avait déjà été hom...
Publication of provisional end result for Vifor Pharma tender offer: P...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022. According to the pr...
Vifor Pharma Ag: 2 directors
Two Directors at Vifor Pharma Ag sold 84,452 shares at 165.000CHF. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Publication of definitive Interim Result for Vifor Pharma tender offer...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022. Taking into acco...
Publication of provisional interim result for Vifor Pharma tender offe...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the interim result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022. According to th...
Nouvelle option de traitement pour les patients atteints de SHPT ‒ Ray...
FRIBOURG, Suisse--(BUSINESS WIRE)-- Vifor Pharma Suisse SA a annoncé aujourd’hui le lancement en Suisse de Rayaldee® (calcifédiol à libération prolongée), le premier et unique médicament administré par voie orale approuvé en Europe pour le traitement de l’hyperparathyroïdie secondaire (SHPT) chez les patients adultes atteints d’insuffisance rénale chronique (IRC) de stade 3 ou 4 avec insuffisance en vitamine D (taux sériques de 25-hydroxyvitamine D < 30 ng/ml). « Nous sommes très heureux de pouvoir proposer Rayaldee® en guise de nouvelle possibilité de traitement pour les patients souffrant d...
Kapruvia® receives positive CHMP opinion for the treatment of moderate...
ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission’s final decision regarding marketing authorization for Kapruvia®. If ...
Vifor Pharma reports sustained growth in 2021
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject® / Injectafer® sales from the second quarter 2021 on, and sustained by positive momentum in the second half of 2021. FINANCIAL PERFORMANCE: SOLID PERFORMANCE IN H2 Reported net sales CHF 1,754.2 million, up 2.8% (up 4.0% at CER) EBITDA CHF 602.0 million, up 4.6% (up 6.6% at CER). Excluding other income, EBITDA increased 10.9% (up 13.0% at CER) Gross pr...
Vifor Pharma enregistre une croissance soutenue en 2021
SAINT-GALL, Suisse--(BUSINESS WIRE)-- Regulatory News: AVIS AD HOC EN APPLICATION DE L’ART. 53 RC Le groupe Vifor Pharma a enregistré en 2021 de solides résultats et une augmentation de la rentabilité, soutenus par une forte reprise des ventes de Ferinject®/Injectafer® à partir du deuxième trimestre 2021 et par la dynamique positive connue au deuxième semestre 2021. PERFORMANCE FINANCIÈRE : SOLIDE PERFORMANCE AU DEUXIÈME SEMESTRE Chiffre d’affaires net de 1 754,2 millions de CHF, soit une hausse de 2,8 % (en hausse de 4,0 % à TCC) EBITDA de 602,0 millions de CHF, soit une hausse de 4,6 ...
Vifor Pharma appoints two new members to the Executive Committee
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr. Oliver P. Kronenberg as members of the Vifor Pharma Executive Committee, effective 1 February 2022. Alexandros Sigalas, a 13-year Executive at Vifor Pharma and currently Global Head of Finance, will become acting Chief Financial Officer and succeeds Colin Bond who retired from the company at the end of 2021 at his own request. The Swiss citizen holds a Licen...
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-ass...
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. The approval is consistent with expectations and overall follows the U.S. Food and Drug Administration (FDA) approval of Tavneos® in October 2021 for the same indication. Tavneos® will r...
CSL Behring AG publishes Offer Prospectus on public tender offer for a...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therap...
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population. 85% of the more than 1,000 patients with either high risk of...
Vifor Pharma and American Regent announce settlement of Injectafer® pa...
ST. GALLEN, Switzerland & SHIRLEY, N.Y.--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sandoz, Inc., that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the U.S. Food and Drug Administration to market a generic version of Injectafer®. Under the terms o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.